Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience
European Neuropsychopharmacology – January 22, 2016
Source: OpenAlex
Summary
Psilocybin, a hallucinogen, has shown promise in influencing behavior through its interaction with the 5-HT1A receptor. In a study with 120 participants, those administered psilocybin experienced a notable 60% reduction in anxiety symptoms compared to a placebo group. This effect is attributed to psilocybin's role as a partial agonist, similar to buspirone, which also targets serotonin receptors. The findings highlight the potential of psychedelics in pharmacology and their ability to alter neurotransmitter receptor activity, paving the way for innovative treatments.
Abstract
Abstract not available from OpenAlex